株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血管新生緑内障:世界の治験動向

Neovascular Glaucoma Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 324944
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
血管新生緑内障:世界の治験動向 Neovascular Glaucoma Global Clinical Trials Review, H2, 2016
出版日: 2016年11月30日 ページ情報: 英文 50 Pages
概要

当レポートでは、血管新生緑内障に関する臨床研究の最新動向について調査し、地域・進捗状況・フェーズ (相) ・募集状況別の実施件数や、代表的なスポンサー、開発中の治療薬の情報、世界各国の主要企業・機関での進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

イントロダクション

  • 血管新生緑内障
  • レポートガイダンス

地域別の治験件数

  • 国別の治験件数および平均参加者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州の主要国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:眼科の治験における血管新生緑内障の割合

G7諸国での治験件数:相 (フェーズ) 別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:眼科の治験における血管新生緑内障の割合

E7諸国での治験件数:相 (フェーズ) 別

E7諸国での治験件数:進捗状況別

相 (フェーズ) 別の治験件数

  • 進行中の治験:相別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数:血管新生緑内障

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 血管新生緑内障の治療薬の治験に携わっている主要企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概況
    • Gene Signal International SA
    • ODIN Biotech Partners, LLC
  • 主要な研究機関/政府機関/病院の治験の概要
    • 熊本大学
    • Federal University of Sao Paulo
    • University of Illinois
    • 島根大学
    • Universidade Federal de Uberlandia
    • Hong Kong Eye Hospital
    • University of Lubeck
    • Faculty of Medicine Siriraj Hospital, Mahidol University
    • Shahid Beheshti University of Medical Sciences
    • Cairo University

5つの代表的な治験のプロファイル

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3972CTIDB

GlobalData's clinical trial report, "Neovascular Glaucoma Global Clinical Trials Review, H2, 2016" provides an overview of Neovascular Glaucoma clinical trials scenario. This report provides top line data relating to the clinical trials on Neovascular Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Neovascular Glaucoma Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
  • Source

List of Tables

  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Region, 2016*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2016*
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, G7 Countries (%), 2016*
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, E7 Countries (%), 2016*
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Neovascular Glaucoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, G7 Countries (%), 2016*
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, E7 Countries (%), 2016*
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Neovascular Glaucoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top